3-(3-methyl-4-nitrophenoxy)pyridine | 163258-42-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(3-methyl-4-nitrophenoxy)pyridine
• CAS: 163258-42-2
• 化学式: C₁₂H₁₀N₂O₃
• 分子量: 230.223
• InChiKey: HXWLDFKWFGCYGP-UHFFFAOYSA-N

物化性质

• 沸点：
  350.9±27.0 °C(Predicted)
• 密度：
  1.269±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  67.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-羟基吡啶 、 5-氟-2-硝基甲苯 在 oil 、 hexanes 、 ice 、 N,N-二甲基甲酰胺 、 乙酸乙酯 、 Brine 、 magnesium sulfate 、 dark oil 作用下， 以 N,N-二甲基甲酰胺 、 Brine 为溶剂， 反应 1.0h， 生成 3-(3-methyl-4-nitrophenoxy)pyridine
  参考文献：
  名称：

  N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR

  摘要：

  本发明提供了式（I）的化合物，它们是5-HT6受体的拮抗剂。

  公开号：

  US20090306110A1

文献信息

• [EN] POLYCYCLIC COMPOUNDS AS INHIBITORS OF BRUTON'S TYROSINE KINASE<br/>[FR] COMPOSÉS POLYCYCLIQUES À UTILISER EN TANT QU'INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2017100662A1

  公开（公告）日：2017-06-15

  The present disclosure is directed to compounds of Formula (I) as Bruton's kinase inhibitors and their preparation, as well as compositions comprising compounds of Formula (I).

  本公开涉及化合物的公式（I）作为Bruton激酶抑制剂及其制备，以及包含化合物的公式（I）的组合物。
• Tryptamine analogues as 5-ht1-like agonists
  申请人：SmithKline Beecham plc

  公开号：US05637593A1

  公开（公告）日：1997-06-10

  A compound of structure (I), in which A.sup.1 is O, S(O).sub.n in which n is 0, 1 or 2, NR, CH.sub.2, or CH(OH); A.sup.2 is a bond or CH.sub.2 ; or A.sup.1 A.sup.2 is CH.dbd.CH; R is hydrogen or C.sub.1-4 alkyl; R.sup.1 is an optionally substituted 6- to 10-membered aryl or heteroaryl ring; suitably R.sup.1 is an optionally substituted 6- 10-membered aryl ring such as phenyl or naphthyl; suitably R.sup.1 is optionally substituted 6- to 10-membered heteroaryl ring, containing from 1 to 4 nitrogen atoms; R.sup.2 is hydrogen, halogen, C.sub.1-4 alkyl, CN, NO.sub.2 or CF.sub.3 ; R.sup.3 is C(R.sup.4)(R.sup.5)CH.sub.2 NR.sup.6 R.sup.7, --CH.dbd.NNHC(NH)NH.sub.2 or a; R.sup.4 and R.sup.5 are independently hydrogen or C.sub.1-4 alkyl; R.sup.6 and R.sup.7 are the same or different and are each hydrogen or C.sub.1-4 alkyl or together with the nitrogen atom to which they are attached form a ring; R.sup.8 is hydrogen, C.sub.1-4 alkyl, or C.sub.3-6 alkenyl; the dotted lines represent an optional bond; and q and m are independently 1 or 2; and pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds are 5-HT.sub.1 -like agonists (or partial agonists) and as such are expected to have utility in medicine in the treatment and/or prophylaxis of migraine, and other conditions associated with cephalic pain, such as cluster headache, headache associated with vascular disorders and other neuralgia. They are also expected to have utility in the treatment of prophylaxis of portal hypertension. ##STR1##

  结构(I)的化合物，其中A.sup.1为O，S(O).sub.n，其中n为0、1或2，NR，CH.sub.2或CH(OH)；A.sup.2为键或CH.sub.2；或A.sup.1 A.sup.2为CH.dbd.CH；R为氢或C.sub.1-4烷基；R.sup.1为可选择取代的6-至10-成员芳基或杂芳基环；适当地，R.sup.1为可选择取代的6-10-成员芳基环，如苯基或萘基；适当地，R.sup.1为可选择取代的6-至10-成员杂芳基环，含有1至4个氮原子；R.sup.2为氢、卤素、C.sub.1-4烷基、CN、NO.sub.2或CF.sub.3；R.sup.3为C(R.sup.4)(R.sup.5)CH.sub.2 NR.sup.6 R.sup.7，-CH.dbd.NNHC(NH)NH.sub.2或a；R.sup.4和R.sup.5独立地为氢或C.sub.1-4烷基；R.sup.6和R.sup.7相同或不同，各自为氢或C.sub.1-4烷基，或者与它们连接的氮原子一起形成环；R.sup.8为氢、C.sub.1-4烷基或C.sub.3-6烯基；虚线表示可选键；q和m独立地为1或2；及其药学上可接受的盐、溶剂和水合物。这些化合物是5-HT.sub.1类似激动剂（或部分激动剂），因此预计在医学上治疗和/或预防偏头痛以及与头痛有关的其他疾病，如集束性头痛、与血管疾病相关的头痛和其他神经痛的条件中具有用途。它们还预计在预防和治疗门脉高压方面具有用途。
• N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor
  申请人：Chen Zhaogen

  公开号：US20060009511A9

  公开（公告）日：2006-01-12

  The present invention provides compounds of formula (I), which are antagonists of the 5-HT 6 receptor.

  本发明提供了式(I)的化合物，它们是5-HT6受体的拮抗剂。
• N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor
  申请人：Eli Lilly and Company

  公开号：US07157488B2

  公开（公告）日：2007-01-02

  The present invention provides compounds of formula I pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are antagonists of the 5-HT6 receptor. The present invention further provides a method of treating disorders associated with 5-HT6 receptors, including schizophrenia, anxiety, Alzheimer's disease, and cognitive disorders selected from the group consisting of age-related cognitive decline, mild cognitive impairment, and dementia, comprising: administering to a patient in need thereof an effective amount of a compound of formula I.

  本发明提供了I式化合物及其药学上可接受的盐和制药组合物，其为5-HT6受体拮抗剂。本发明还提供了一种治疗与5-HT6受体有关的疾病的方法，包括精神分裂症、焦虑症、阿尔茨海默病和从年龄相关的认知衰退、轻度认知障碍和痴呆症中选择的认知障碍，该方法包括：向需要接受治疗的患者施用I式化合物的有效量。
• N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor
  申请人：Eli Lilly

  公开号：US08044090B2

  公开（公告）日：2011-10-25

  The present invention provides compounds of formula (I), which are antagonists of the 5-HT6 receptor.

  本发明提供了式（I）的化合物，它们是5-HT6受体的拮抗剂。